

1 Navigating the chaos of psychedelic fMRI 2 brain-entropy via multi-metric evaluations of 3 acute psilocybin effects

4 Drummond E-Wen McCulloch^{1,2,†}, Anders Stevnhoved Olsen^{1,3,†}, Brice Ozenne^{1,4}, Dea Siggaard
5 Stenbæk^{1,5}, Sophia Armand^{1,5}, Martin Korsbak Madsen^{1,6}, Gitte Moos Knudsen^{1,7}, Patrick MacDonald
6 Fisher^{1,8}

7 ¹Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

8 ²Faculty of Health and Medical Sciences, University of Copenhagen, Denmark

9 ³Department of Applied Mathematics and Computer Science, Technical University of Denmark, Kgs. Lyngby,
10 Denmark

11 ⁴Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark

12 ⁵Department of Psychology, University of Copenhagen, Denmark

13 ⁶Department of Psychiatry Svendborg, Svendborg, Denmark

14 ⁷Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

15 ⁸Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark

16 [†]These authors contributed equally to this work

17 Abstract

18 A prominent theory of psychedelics is that they increase brain entropy. Twelve studies have evaluated
19 psychedelic effects on fMRI brain entropy quantifications, no findings have been replicated. Here we
20 evaluated these metrics in an independent 28-participant healthy cohort with 121 pre- and post-psilocybin
21 fMRI scans. We assessed relations between brain entropy and plasma psilocin, brain serotonin 2A receptor
22 occupancy, and a subjective drug intensity rating using linear mixed-effects models. We observed
23 significant positive associations for Shannon entropy of path-length, instantaneous correlation distributions,
24 and divergent associations of sample entropy at varying time-scales. We did not observe significant effects
25 for 8 of 13 entropy metrics. Brain entropy quantifications showed limited inter-measure correlations. Our
26 observations support a nuanced acute psychedelic effect on brain entropy, underscoring the need for
27 replication and that these metrics do not reflect a singular construct. Our findings highlight candidate brain
28 entropy metrics that may mediate clinical effects of psychedelics.

29 Introduction

30 Psychedelic drugs induce profound altered states of consciousness including affective, sensory and
31 cognitive effects mediated by activation of downstream pathways initiated by agonism at the brain serotonin
32 2A receptor¹⁻⁴. In combination with psychological support, clinical studies up to phase 2b indicate
33 promising clinical efficacy of psychedelics in the treatment of affective and behavioural neuropsychiatric
34 disorders that may be associated with their acute effects^{5-10,10-12}. Similarly, psychedelics induce acute and
35 lasting effects on behaviour and personality in healthy participants¹³⁻¹⁵. In parallel to evaluating clinical
36 treatment effects, human brain functional magnetic resonance imaging (fMRI) has begun to shed light on
37 neural pathways affected by psychedelics¹⁶.


38 Several prominent theories of critically relevant psychedelic effects on brain function have been advanced
39¹⁷. A prominent theory is the “Entropic Brain Hypothesis” (EBH), which posits that the 'richness' of the
40 phenomenology of the acute psychedelic state reflects brain-wide increases in entropy of functional brain
41 signals^{18,19}. The concept of "entropy" serves as a quantification of the degree of information or complexity
42 contained in a system; it is typically expressed in bits, without physical dimensions. Entropy has been
43 conceptualised as a metric of information content and is largely defined in terms of a probability
44 distribution; the metric is commonly referred to by the eponymous name “Shannon entropy” $H(X) =$
45 $-\sum_{x \in X} p(x) \cdot \log_2 p(x)$ where $H(X)$ refers to the Shannon entropy of probability mass function X
46 containing bins (x) with height (p)²⁰. Other entropy metrics have been defined, e.g., Lempel-Ziv complexity
47 and sample entropy²¹⁻²⁴, and adapted to characterise information contained in various objects, e.g., complex
48 networks or graph structures²⁵.

49 To date, 12 studies have evaluated either acute or lasting psychedelic effects on the information-entropy of
50 brain-activity or connectivity using blood oxygen level dependent (BOLD) fMRI data (Figure 1), one of
51 which evaluates two metrics, thus 13 entropy metrics have been previously evaluated in this field. Four
52 papers analysed data from a study evaluating 2mg intravenous psilocybin administration in up to 15 healthy
53 participants^{19,26-28}. Two papers reported effects from a study evaluating 75µg intravenous LSD
54 administration in 15 healthy participants^{29,30}. Two papers evaluated data from both datasets^{31,32}. Three
55 papers reported effects from a study evaluating oral ayahuasca administration, containing 96-160mg DMT
56 and 25.2-42mg harmine (a monoamine oxidase inhibitor that facilitated the oral bioavailability of DMT) in
57 9 healthy participants³³⁻³⁵. Finally, one paper reported effects from a study evaluating lasting effects of
58 25mg/70kg bodyweight orally administered psilocybin in 11 healthy participants³⁶. Notably, and
59 highlighted in a recent review¹⁶, each of these reports quantified a distinctly different metric of brain
60 entropy. Here we group these metrics into three categories: 1) “static connectivity”, 2) “dynamic
61 connectivity”, i.e., the time-varying relation between two or more time-series, 3) “dynamic activity”, i.e.,
62 the entropy of regional time-series (Figure 1). Nine of these metrics are based on the Shannon entropy of
63 distributions, three are Lempel-Ziv complexity metrics of a time-series and one is the sample entropy of a
64 time-series. Taken together, although there is a clear interest in evaluating psychedelic effects on brain
65 entropy, prominent limitations include that none of these measures have been evaluated in an independent
66 cohort, the set of effects have been evaluated in only a few datasets, some with atypical modes of drug
67 administration, and the inter-correlation between these metrics has not been considered. Previous studies
68 compared pre-drug or placebo and a single post-drug scan. For the most part, these previous studies report
69 increased brain entropy with only a few exceptions, e.g., two studies report non-significant psilocybin


70 effects and one study reports no lasting changes (Figure 1, Table 1). See Supplementary Table S1 for more
71 details about the previous studies. Previous fMRI studies have reported reduced brain entropy in other states
72 of "reduced consciousness", including NREM sleep ³⁷, minimal-consciousness ³⁸, and anaesthesia ³⁹,
73 whereas other studies have shown increased brain entropy following caffeine ⁴⁰ and Salvinorin A intake ⁴¹.

74 In the current study, we sought to evaluate the acute effects of 0.2-0.3mg/kg psilocybin administration on
75 these 13 brain entropy metrics in an independent dataset of 28 healthy individuals. Based on the entropic
76 brain hypothesis, we hypothesised that brain entropy metrics would be increased following psilocybin
77 administration. Participants completed a 5 or 10-min resting-state fMRI scan a single time before, and
78 multiple times following psilocybin administration (121 total scan sessions). All scans for each participant
79 were performed on one of two scanners. Each scan was accompanied by a self-report measure of subjective
80 drug intensity (SDI) and a blood sample to quantify plasma psilocin level (PPL), from which brain serotonin
81 2A (5-HT_{2A}) receptor occupancy (Occ_{2A}), was estimated based on its relation to PPL established in a
82 previous study from our lab ². We evaluated the relations between each entropy metric and SDI, PPL and
83 Occ_{2A} using linear mixed-effect model with a subject-specific random intercept and correction for age, sex,
84 scanner, and motion (see Methods Supplementary Material for more details). We report uncorrected
85 permutation p-values (p_{perm}) for each metric producing a single whole-brain value. For entropy metrics
86 producing regional values, we report family-wise error rate corrected permutation p-values (p_{FWER}) with
87 correction across all regions within each metric using maxT correction ⁴². We report as significant those
88 metrics which were significantly (i.e., $p < 0.05$) associated with SDI, PPL and Occ_{2A} , collectively referred
89 to as "PsiFx". Standardised effect sizes are reported (Pearson's rho). This evaluation was repeated across
90 two parcellation strategies and seven pre-processing pipelines to explore the robustness of effects to pre-
91 processing decisions. Finally, we explored the inter-correlation between brain entropy metrics to
92 characterise their associations.


Dynamic Activity



Static Connectivity



Dynamic Connectivity



94 **Figure 1:** Overview of previous psychedelic fMRI entropy quantifications. Methods are grouped according
95 to the type of brain entropy metric. Symbols in the top left of each box represent the dataset that the original
96 publication analysed. LSD_{IV} (blue) refers to data collected in relation to a 75 µg intravenous LSD
97 administration (n ≤ 15), Psi_{IV} (green) refers to data collected in relation to a 2 mg intravenous psilocybin
98 administration (n ≤ 15), Ay (orange) refers to data collected in relation to an oral ayahuasca administration
99 (n = 9), and Psi_L (green oval) refers to data collected one-week before, one-week after, and one-month after
100 a 25 mg/70 kg oral psilocybin administration (n = 11). Brain images show an axial slice illustrating the
101 parcellation/atlas used. Images in the top right describe the input into the entropy function as one of "region-
102 wise connectivity matrix", "ROI-wise BOLD signal" and "voxel-wise BOLD signal". Illustrations in the
103 lower part of each box graphically represent simplified analysis steps for each method. The original
104 publication for each metric is denoted in the bottom left corner of each box. See Supplementary Table 1 for
105 more details.

106 Results

107 Participants showed substantial SDI and PPL following drug administration as anticipated (Supplementary
108 Figure S1). See Figure 1, Supplementary Table S1 and Table 1 for a summary of entropy metrics, previous
109 findings, and our findings respectively.

110 Entropy of Static Connectivity

111 Out-network Connectivity Distribution

112 Shannon entropy of regional out-network connectivity was not significantly associated with psilocybin
113 effects (PsiFx) in any of the 181 non-cerebellar brain regions after controlling for multiple comparisons
114 ($p_{\text{FWER}} > 0.07$ for all regions for at least one of PsiFx, Supplementary Table S2).

115 Degree Distribution

116 The entropy of degree distribution at a correlation coefficient threshold corresponding to a mean degree of
117 27 was not associated with any of PsiFx ($p_{\text{perm}} > 0.18$, Figure 2A). We also did not observe significant
118 effects for thresholds producing a mean degree between 1 and 48 (Supplementary Table S3).


119 Path-length Distribution

120 The entropy of path-length distribution was significantly positively associated with PsiFx at the a priori
121 described threshold producing mean degree 27 ($p_{\text{perm}} < 0.04$, Figure 2B). The associations were weak to
122 moderate (Pearson's rho = 0.39, 0.27, and 0.23 for PPL, Occ_{2A} and SDI, respectively). Significant weak to
123 moderate positive associations with PsiFx were also observed across thresholds producing mean degrees
124 from 22 to 38 (Supplementary Table S3).

125 Von Neumann Entropy

126 The Von Neumann entropy of correlation matrices was not significantly associated with PsiFx ($p_{\text{perm}} > 0.35$,
127 Figure 2C and Supplementary Table S3).

128
129



130
131 **Figure 2:** Scatter plots describing the relation between static connectivity entropy and PPL. Y-axis values
132 are partial residuals i.e., entropy values adjusted for age, sex, MR scanner and motion. Degree distribution
133 and path-length distribution statistics are computed using a correlation coefficient threshold corresponding
134 to a mean-degree of 27.

135

136 Entropy of Dynamic Connectivity

137 Intra-network Synchrony Distribution

138 Intra-network synchrony distribution was not significantly associated with PsiFx in any of nine networks
139 (All $p_{\text{FWER}} > 0.98$, Supplementary Table S2, Supplementary Figure S2).

140 Motif-connectivity Distribution

141 The four-ROI motif-connectivity state distribution was not significantly associated with PsiFx at any
142 window length from 15 to 150s except a single weak association at window-length 100s ($p_{\text{perm}} < 0.05$,
143 Pearson's rho 0.30, 0.25, and 0.24 for PPL, Occ_{2A} , and SDI, respectively) surrounded by non-significant
144 findings (Supplementary Figure S3 and Supplementary Table S3).

145 LEiDA-state Markov-rate

146 LEiDA-state Markov-rate was not significantly associated with PsiFx ($p_{\text{perm}} > 0.7$ for all PsiFx, Figure 3A,
147 Supplementary Table S3).

148 Meta-state Complexity


149 Meta-state entropy was positively associated with Occ_{2A} ($p_{perm} = 0.03$) and SDI ($p_{perm} = 0.003$), but not PPL
150 ($p_{perm} = 0.076$, Figure 3B). Associations were weak (Pearson's $\rho = 0.22$, 0.33 , and 0.20 for Occ_{2A} , SDI,
151 and PPL, respectively; Supplementary Table S3).

152 Integration/Segregation-state Distribution

153 Integration sub-state entropy was not significantly associated with PsiFx ($p_{perm} > 0.06$ for all PsiFx, Figure
154 3C, Supplementary Table S3).

155

156



157


158 **Figure 3:** Scatter plots and linear models describing the relation between whole-brain dynamic connectivity
159 entropy measures and plasma psilocin levels. Y-axis values are partial residuals i.e., entropy values adjusted
160 for age, sex, MR scanner and motion. Panel B (Meta-state complexity) shows a non-significant association
161 with PPL but this entropy metric does show a significant linear relation with Occ_{2A} and SDI.

162

163 Dynamic Conditional Correlation Distribution

164 Dynamic conditional correlation entropy was significantly positively associated with PsiFx in 35 of 36
165 network-network connections (18/36 $p_{FWER} < 0.0001$, i.e., observed data superseded all permutations, 29/36
166 $p_{FWER} < 0.001$, 35/36 $p_{FWER} < 0.05$; Figure 4A; Supplementary Table S2). Associations were moderate to
167 strong (Pearson's ρ range: 0.35 to 0.78 , Supplementary Table S2). The one association with at least one
168 non-significant relation was for edges within the motor cortex.

169



170


171 **Figure 4: A:** Heatmap of the Pearson's correlation and p-values for the association between Dynamic
 172 Conditional Correlation entropy and plasma psilocin level for each within and between network entropy
 173 estimate. *** represents $p_{FWER} < 0.0001$, ** $p_{FWER} < 0.001$, and * $p_{FWER} < 0.05$ for associations with PPL.
 174 **B:** A scatter plot of the network edge with the strongest association between DCC entropy and PPL
 175 (Pearson's Rho = 0.74). Y-axis values are partial residuals i.e., entropy values adjusted for age, sex, MR
 176 scanner and motion.

177

178 Entropy of Dynamic Activity

179 Multi-Scale Sample Entropy

180 At scale 1, (i.e., no time-series compression), sample entropy was significantly positively associated with
 181 PsiFx ($p_{FWER} < 0.05$) in 7 of 17 networks (i.e., Central Visual, Dorsal Attention A, Control A, B and C,
 182 Default-Mode A and C). At scales 2, 3, and 4, no associations were significantly associated with PsiFx
 183 ($p_{FWER} > 0.05$). At scale 5, sample entropy was significantly negatively associated with PsiFx in 14 of 17
 184 networks; Control A and C and Default-Mode A ($p_{FWER} < 0.001$), Somatomotor A, Dorsal Attention A and
 185 B, Salience-Ventral-Attention B, Limbic B, Control B, Temporal-Parietal, Default-Mode B and C ($p_{FWER} <$
 186 0.05 , Figure 5, Supplementary Table S2). Scale 1 associations were weak to moderate (Pearson's rho range:
 187 0.26 to 0.47), as were Scale 5 associations (Pearson's rho range: -0.27 to -0.49).




188

189 **Figure 5:** Forest plots representing the estimate of the association between sample entropy and PPL in each
 190 network of the Yeo-17 network parcellation and at each of scales 1 to 5. Colours represent networks and
 191 error bars represent the 95% confidence interval. *** $p_{FWER} < 0.0001$, ** $p_{FWER} < 0.001$ and * $p_{FWER} < 0.05$
 192 for associations with PPL.

193 Spatial and Temporal Dynamic BOLD Complexity

194 Temporal BOLD complexity (LZct) was not associated with PPL ($p_{\text{perm}} = 0.14$, Figure 6B) but was
195 associated with Occ_{2A} ($p_{\text{perm}} = 0.03$) and SDI ($p_{\text{perm}} = 0.009$). Associations were weak (Pearson's rho = 0.23,
196 0.30 and 0.17 for Occ_{2A}, SDI, and PPL respectively). Spatial BOLD complexity (LZcs) was not
197 significantly associated with PsiFx ($p_{\text{perm}} > 0.6$, Figure 6A, Supplementary Table S3).

198
199



200
201 **Figure 6:** Scatter plots and linear models describing the relation between spatial (A) and temporal (B)
202 Lempel-Ziv entropy of dynamic BOLD activity and PPL. Y-axis values are partial residuals i.e., entropy
203 values adjusted for age, sex, MR scanner and motion. Temporal BOLD complexity (LZct) was
204 significantly, but weakly associated with both Occ_{2A} and SDI despite not being significantly associated with
205 PPL.

206 Effect of Parcellation

207 To evaluate PsiFx on brain entropy metrics using a common parcellation, all analyses were re-run using an
208 atlas combining the Schaefer-100 (7 Yeo networks) and Tian-16 subcortical atlases^{43,44}. Path-length
209 distribution showed a weak positive association with all PsiFx at mean degrees 31 to 38. Meta-state
210 complexity was weakly positively associated with Occ, but not PPL nor SDI. LEiDA-state Markov-rate
211 was weakly negatively associated with all PsiFx and DCC distribution was weak-to-strongly associated
212 with all PsiFx across most network edges. Sample Entropy was weak-to-moderately associated with PsiFx
213 at scale 1 but no significant associations were observed at longer scales, though the trend of increased
214 entropy at short scales and decreased entropy at long-scales was maintained. All other metrics were not
215 significantly associated with PsiFx. See Table 1 for a summary and Supplementary Table S5 for detailed
216 results.

217 Effect of Pre-processing Pipeline

218 To explore moderating effects of pre-processing pipelines on PsiFx associations with brain entropy metrics,
219 we considered six variations on the above Schaefer-100, Yeo-7, Tian-16 pipeline: 1) including global-signal
220 regression, 2) removal of the low-pass filter (0.09 Hz), 3) applying a narrow bandpass filter (0.03-0.07 Hz),
221 4) regressing 24 motion parameters, 5) omitting scrubbing, and 6) a stricter scrubbing threshold ($z > 3$ SDs,
222 motion > 0.5 mm). Some brain entropy metrics were relatively robust to pre-processing pipeline, i.e.,
223 showing significant associations with PsiFx across most pipelines: sample entropy (scale 1), dynamic
224 conditional correlation entropy, meta-state complexity and path-length distribution. Some metrics were
225 consistently not associated with PsiFx across pipelines: motif-connectivity distribution, I/S state
226 distribution, LEiDA-state distribution and Intra-network synchrony. Some metrics were significantly
227 associated with PsiFx for some pipelines and not others: temporal BOLD complexity (i.e., only significant
228 with no-scrubbing and strict scrubbing) and Von Neuman Entropy (i.e., only significant with GSR and
229 significant associated with SDI and Occ_{2A} when the low-pass filter was removed). Two pre-processing
230 pipelines modulating signal-filtering had substantial effects on results. First, removing the low-pass filter
231 flipped the sign to negative for the association between PsiFx and dynamic conditional correlation entropy
232 and sample entropy (scale 1). Second, a narrow-band filter (0.03-0.07 Hz) made non-significant all PsiFx
233 associations with dynamic and dynamic-connectivity metrics. See Supplementary Table S8 for a summary
234 and Supplementary Table S9 for a full detailing of pre-processing effects.

235 Moderating Effect of Scanner


236 To evaluate scanner effects on observed associations, we fit linear mixed models estimating the moderating
237 effect of scanner. Of the three entropy metrics that had a significant association with PsiFx, we observed a
238 significant moderating effect of scanner on the relation between PPL and entropy for path-length
239 distribution over the range of thresholds at which we observe significant associations with PsiFx. The nature
240 of this interaction was that for scanner A the effect was closer to zero than for scanner B. We also show a
241 significant moderating effect of scanner for Sample Entropy scale 5 across many ROIs that are significantly
242 associated with PsiFx. However, the observed effect is the same direction for scanner A and B, only
243 numerically stronger for scanner A. We do not observe a significant moderating effect of scanner for DCC
244 entropy, further supporting the robustness of this metric. For entropy metrics that were not associated with
245 PsiFx in the main model, we observed moderating effects of scanner for I/S-state distribution, some
246 window-lengths of motif-connectivity distribution, some ROIs of out-network connectivity, degree
247 distribution, and some sample entropy scale 4 ROIs. See Supplementary Table S6 for full results.

248 Correlation Between Whole-brain Entropy Quantifications

249 We estimated the correlation between whole-brain entropy metrics to explore their association with one
250 another across all included scans. Some pairs of metrics were both positively correlated and negatively
251 correlated and some pairs were effectively not correlated with one another (Figure 7). After correction for
252 multiple comparisons, five entropy quantification pairs were positively related (LZcs & LZct, LZcs & Von-
253 Neumann, Path-distribution & Degree-distribution, LEiDA state & Von-Neumann, Motif Connectivity
254 Distribution-window100 & Von-Neumann) and four were negatively related (Path-distribution & LEiDA
255 state, Path-distribution & Von-Neumann, Degree-distribution & LEiDA state, Degree-distribution & Von-

256 Neumann). LZcs was significantly negatively associated with motion. See Supplementary Table S4 for
 257 pairwise correlation coefficients and p-values.

258



259
 260 **Figure 7:** Heatmap showing the correlations between whole-brain entropy metrics and motion. Colours
 261 represent the Pearson's correlation coefficient. * represents $p_{\text{corr}} < 0.05$. I/S state, Integration/Segregation
 262 state distribution; MCD, Motif connectivity distribution (with either 100 or 15 second windows); LZcs,
 263 Spatial Lempel-Ziv complexity. LZct, Temporal Lempel-Ziv complexity.

Entropy	Original dataset	Original findings	Our findings (original atlases)	Our findings (common atlas)
Static Connectivity				
Out-network connectivity	IV Psi	Region-specific effects	Not associated with PsIFx	Not associated with PsIFx
Degree distribution	Oral Aya	Increased	Not associated with PsIFx	Not associated with PsIFx
Path-length distribution	Oral Aya	Increased	Weak-moderate association with PsIFx†	Weak-moderate association with PsIFx†
Von Neumann Entropy	Oral Aya	Numerically increased	Not associated with PsIFx	Not associated with PsIFx
Dynamic Connectivity				
Intra-network synchrony	IV Psi	Increased (some networks)	Not associated with PsIFx	Not associated with PsIFx
Motif-connectivity distribution	IV Psi	Increased	Not associated with PsIFx	Not atlas dependent
Meta-state complexity	IV Psi & IV LSD	No change	Weak association with SDI and Occ but not PPL	Weak association with Occ but not SDI or PPL
I/S state distribution	IV LSD	No change	Not associated with PsIFx	Not associated with PsIFx
LEIDA state Markov Rate	IV LSD	Not reported	Not associated with PsIFx	Weak negative association with all PsIFx
Edge-wise DCC distribution	Oral Psi*	No persisting change	Moderate-strong association with all PsIFx all networks except within motor cortex	Weak-strong association with all PsIFx in most networks
Dynamic Activity				
Multi-scale sample entropy	IV LSD	Increased at scales 1, 2 and 3. Decreased at scale 5	Weak-moderate association with all PsIFx in several networks. Positive at scale 1, negative at scale 5	Weak-moderate association with all PsIFx in several networks. Positive at scale 1
BOLD complexity (spatial)	IV Psi & IV LSD	Increased (LSD) No change (psilocybin)	Not associated with PsIFx	Not associated with PsIFx
BOLD complexity (temporal)	IV Psi & IV LSD	Not reported	Weak association with SDI and Occ but not PPL	Not associated with PsIFx

*Investigates persisting effects at 1 week and 1 month post-psilocybin administration

† at thresholds producing a mean degree of 22-38

‡ at thresholds producing a mean degree of 31-38

265 **Table 1:** Summary of entropy quantification methods, previous findings, and findings reported within this
266 manuscript. For the “Original findings” and “Our findings” columns, grey cells describe no association of
267 effect, light grey refers to no reporting of acute effects on brain entropy, yellow describes marginal
268 effects, and green statistically significant effects. For a more in-depth evaluation of our findings please
269 see supplementary tables 1 and 2.

270 Discussion

271 Overview

272 Recent studies have reported acute psychedelic effects on functional brain entropy, but to date none of these
273 metrics have been evaluated in an independent sample. In this study we evaluated 13 previously reported
274 entropy metrics in a novel sample of 28 healthy participants scanned with BOLD fMRI before and several
275 times after psilocybin with concomitant measurements of subjective drug intensity and plasma psilocin
276 level. We observed statistically significant psilocybin effects that echoed previous reports for only two brain
277 entropy metrics: path-length distribution, wherein we replicate increased entropy at previously reported
278 thresholds; and sample entropy, wherein we replicate a previously observed increase in entropy at short
279 scales and decrease at long scales. We observed a strong positive relation between psilocybin effects and
280 brain entropy measured by Dynamic Conditional Correlation analyses that has not been previously reported.
281 Two Lempel-Ziv complexity metrics showed some evidence for associations with psilocybin effects. For 8
282 of 13 brain entropy metrics previously reported, we did not observe a significant association with psilocybin
283 measures and we see limited correlation between entropy metrics. These mixed findings underscore the
284 importance of corroborating outcomes in independent datasets. Although we observe some evidence
285 supporting the entropic brain hypothesis, these variable findings underscore the broadness of this theory
286 and the need to more clearly establish which brain entropy metrics of functional brain imaging signals are
287 acutely affected by psychedelics.

288 Path-length Distribution

289 We report a significant positive association between the Shannon entropy of the distribution of path lengths
290 across the whole brain as previously reported by Viol and colleagues³⁴ and all three psilocybin metrics
291 evaluated: PPL, Occ_{2A}, and SDI. We observed statistically significant associations at a range of correlation
292 coefficient thresholds that produce graphs with a mean degree from 22 to 38, Viol and colleagues reported
293 significant differences between conditions at thresholds producing mean degrees from 24 to 35.
294 Characteristic path length is a description of the number of edges that must be traversed to get from any
295 one brain region to another, a putative measure of capacity for information flow. Our results suggest that
296 one of the effects of psilocybin on the brain can be described as a broadening of the histogram of path
297 lengths across region-to-region connections in the brain. Notably, this does not imply that the average path
298 length is shorter or longer, only that there is a wider distribution of these across the whole brain i.e., it is
299 more equally likely that the path-length between any two nodes is 1, 2 or 3 instead of being more likely to
300 be one of these. Our convergent results are encouraging considering that the previously reported dataset
301 used a different drug (ayahuasca, which contains MAOIs as well as the psychedelic N,N-
302 dimethyltryptamine) and different imaging parameters, suggesting robustness of the metric. This
303 association with PsiFx was relatively robust to pre-processing strategies, though did appear sensitive to
304 scanning parameters between the two explored in this study. Thus, path-length entropy may be a useful
305 candidate biomarker of neural psychedelic effects, though associations were weak-moderate and
306 interpretation is not straightforward. We are not aware of other studies evaluating the entropy of path-length
307 distribution so comparison to other drugs or psychiatric conditions are not yet possible and should be
308 evaluated in future studies.

309 Dynamic Conditional Correlation Distribution

310 We observed a statistically significant positive relation between psilocybin effects and Dynamic
311 Conditional Correlation (DCC) Distribution for all within or between network relations except within the
312 motor network. DCC distribution is a measure of the width of the distribution of instantaneous connectivity
313 values for any region-region edge across each scan. The previous study found no change in DCC
314 distribution at one-week and one-month post administration³⁶ and importantly did not evaluate acute effects
315 during psilocybin. We observed moderate to strong correlations with psilocybin effects (i.e., Pearson's rho
316 with PPL > 0.7 for three edges, all including DMN (DMN-DMN, DMN-Frontoparietal, DMN-Medial
317 Frontal), and Pearson's rho > 0.5 for 28/36 network edges). The strength of these associations is remarkable,
318 perhaps as large as any previously reported fMRI effect of psychedelic action, suggesting that DCC
319 distribution may be a strong candidate neural correlate of acute psychedelic effects and among the strongest
320 correlations observed in pharmaco-fMRI. Our results suggest that psilocybin increases the variability of
321 connectivity between regions across time across almost all region-region pairs, which are summarised into
322 networks. Furthermore, this association was robust to most pre-processing strategies and was similar across
323 the two scanning parameters applied in this study. As above, we are not aware of other pharmaco-fMRI
324 studies evaluating DCC distribution. Notwithstanding, the sheer magnitude of the observed associations
325 suggests DCC distribution may be a sensitive marker for acute psychedelic effects on the brain and so we
326 encourage independent replication.

327 Multi-scale Sample Entropy

328 We observed a significant positive relation between psilocybin effects and scale-1 sample entropy (i.e.,
329 temporal resolution = 2-seconds) in seven out of 17 brain networks. Conversely, we observed a significant
330 negative relation between scale 5 sample entropy (temporal resolution = 10-seconds) in 14 out of 17
331 networks. This association at short-scale was somewhat robust to pre-processing pipelines and at all scales
332 consistent across scanning parameters. Multi-scale sample entropy measures the irregularity of a signal
333 over its entire length. Increased sample entropy in most networks at scale-1 and decreased sample entropy
334 at scale-5 align in both cases with the original observation²⁹. Unfortunately, we were unable to align the
335 previously reported network labels with available versions of the atlas; thus, it is hard to resolve the spatial
336 overlap between studies. fMRI-measured multi-scale sample entropy has been shown to be increased in the
337 default-mode, visual, motor and lateral-prefrontal networks following caffeine⁴⁰ and decreased at scale 1
338 during sleep³⁷, although certain parameters used in their calculations were different to those employed here.
339 As such, it is possible that the effects that we, and Lebedev and colleagues, observed may reflect differences
340 in wakefulness and may thus be non-specific to psychedelic effects. Positive symptoms of schizophrenia
341 have been positively associated with sample entropy at scales 1 and 2, and negatively associated in certain
342 brain regions at scales 3, 4, and 5⁴⁵. This is consistent with our observations and is also phenomenologically
343 consistent, as the high-dose psychedelic state has some overlap with some positive symptoms of
344 schizophrenia e.g., verisimilitude, alterations in visual perception (though psychedelics do not normally
345 produce 'true' hallucinations, i.e., sensory appearances indistinguishable from reality, as are present in
346 schizophrenia), and sense of self. We are aware of the problematic history of psychedelic
347 'psychotomimetic' research and urge caution in overinterpretation of this apparent convergence⁴⁶. Our
348 convergent results with Lebedev and colleagues are intriguing considering that the original paper reported
349 effects following intravenous LSD administration whereas we administered psilocybin orally. Taken

350 together, divergent effects on sample entropy at short and long temporal resolutions may be a candidate
351 biomarker for psychedelic effects, if they cannot be explained by, e.g., wakefulness state.

352 Lempel-Ziv Complexity

353 Intriguingly, Lempel-Ziv complexity of two measures (meta-state complexity and temporal BOLD
354 complexity (LZct)) were significantly positively associated with Occ_{2A} and SDI, but not PPL. LZct was
355 significantly moderately associated with all PsiFx in the no-scrubbing and strict-scrubbing pre-processing
356 pipelines, and meta-state complexity was significantly weak-moderately associated with at least one PsiFx
357 in all but one pre-processing pipeline. The original study of meta-state complexity does not report a
358 statistical analysis of intravenous LSD nor intravenous psilocybin effects, but the data are publicly available
359 and do not support a significant effect of either drug³¹. The original study of BOLD complexity reports an
360 increase in spatial BOLD complexity following LSD, but not psilocybin and does not report any findings
361 pertaining to temporal BOLD complexity. We speculate that the less significant relations with PPL reflect
362 that PPL is non-linearly related to brain 5-HT_{2A} receptor occupancy, which is ultimately responsible for
363 the neural effects of psychedelics². Therefore, PPL may be a less precise metric of acute psychedelic effects
364 on brain function. One MEG and four EEG studies have reported increased LZc following psychedelic
365 administration⁴⁷⁻⁵¹, providing convergence for its utility as a marker of psychedelic effects, however one
366 reports increases in LZct in the absence of subjective drug effects, indicating a potential epiphenomenon.
367 Across previous studies analysing regional timeseries, there is inconsistency in the quantification of LZc in
368 the temporal (LZct) and spatial (LZcs) domain. Our borderline statistically significant associations were
369 observed for LZct only. It is our perspective that LZct is more sensible and should be used in future studies
370 as it preserves region-specific temporal information, whereas LZcs is sensitive to arbitrary region order.

371 Null Findings

372 We did not observe a significant association between 8 of the 13 brain entropy metrics considered here
373 (Table 1). Of these seven metrics, the original studies reported either increased entropy following
374 psychedelic drug administration^{19,27,28,35}, no effect³⁰, or did not formally evaluate the effect of psychedelic
375 drug administration^{26,33} (Table 1, Supplementary Table S1). Our observed entropy estimates for
376 hippocampal-ACC motif entropy are markedly different from those previously reported²⁸. We are
377 concerned that the originally reported values are not mathematically possible, see the Supplementary Text
378 and Supplementary Figure S3 for a detailed consideration. Although our null findings with respect to these
379 metrics does not establish that they have no relation to acute psychedelic drug effects, they imply a smaller
380 relation that limits their utility as biomarkers of acute psychedelic effects. The discrepancy between our
381 observations and those reported previously underscores the need to replicate or corroborate findings in
382 independent cohorts to validate initial reports.

383
384 Our inability to replicate previous findings may be due to greater statistical power and different statistical
385 models i.e., linear regression with PsiFx. Incongruence may also be attributed to differences in data
386 collection. All previous studies reporting acute effects on brain entropy administered either 2mg of
387 intravenous psilocybin, 75µg of intravenous LSD or 96-160mg of oral DMT with harmine, yet we
388 administer 0.2-0.3mg/kg oral psilocybin, though the acute effect appear similar, we cannot rule out
389 differences due to drug or route of administration. However, if entropic brain effects are not consistent

390 across drugs this would indicate that these metrics are not useful neural correlates of the psychedelic
391 experience. We encourage all future fMRI studies evaluating psychedelic effects on brain function to
392 measure subjective drug intensity at time of scanning and to collect plasma samples for quantification of
393 plasma drug levels as described in the psychedelic fMRI consensus paper¹⁶.

394 Inter-correlation Between Entropy Metrics

395 Despite the large set of brain entropy metrics that have been reported previously, no studies have considered
396 whether these measures are inter-correlated. We observed positive associations between path-length and
397 degree distribution, which are based on the same graph-theory representation of connectivity, and between
398 LZcs and LZct which are conceptually very much related. Notably, we observed four pairs of brain entropy
399 metrics that were significantly negatively correlated. This highlights the importance of specificity in
400 describing “brain entropy”. Many of these metrics represent distinctly different constructs, their individual
401 meaning and collective representation of psychedelic effects is muddled by superficially considering them
402 all metrics of “brain entropy”. Future studies should be cognisant of this variable relation in considering
403 whether findings are consistent or convergent across studies.

404 Alternative Neuroimaging Techniques

405 Although we focus here on fMRI quantifications of entropy, it is worth noting that psychedelic effects on
406 brain entropy, specifically LZc, have been applied to five original MEG and EEG datasets, over eight papers
407⁴⁷⁻⁵⁴. The entropy measures applied in these studies leverage the high temporal sampling rate that is not
408 clearly applicable to temporally slower fMRI and were not evaluated here. Further, the methods capture
409 different aspects of physiological response to psychedelics. Future work evaluating psychedelic effects on
410 brain entropy using multimodal neuroimaging and evaluating relations between alternative quantifications
411 of brain-entropy will contribute meaningfully to the field.

412 Limitations

413 Our study is not without its limitations. Brain imaging data were acquired on two different MRI scanners
414 with different sequences (e.g., different TRs) requiring temporal downsampling of some data to match the
415 other. However, each participant was scanned on only one scanner, enabling us to map within-subject
416 changes onto psilocybin effects independent of scanner differences. Our study did not include a placebo
417 condition, but we did acquire a pre-drug scan with which we estimated brain entropy metrics in the absence
418 of psilocybin effects. Due to the large within-subject variability in fMRI outcomes in participants scanned
419 several days apart, pre-drug vs post-drug scans performed on the same day may be superior to placebo scans
420 performed weeks apart for evaluating drug effects because it limits this within-subject variance component
421⁵⁵. PPL and SDI were associated with increased motion in the scanner, see Supplementary Figure S4;
422 although we included an estimate of motion as a covariate in our models, employed scrubbing, motion
423 correction and denoising strategies, and show that motion was not positively associated with any whole-
424 brain entropy metrics, we cannot rule out that motion confounds our reported effects. It has been reported
425 in many groups that head motion is increased following psychedelic drug administration so this is not a
426 limitation unique to our data⁴⁸. Most fMRI scans were 10 minutes long, though some were only five. This
427 may not be long enough to derive stable estimates of brain entropy metrics, e.g., previous studies have

428 recommended >13 minutes for single-echo fMRI⁵⁶. Future studies, e.g., using openly available data with
429 longer scan durations, could inform recommended scan durations to establish stable brain entropy estimates
430 or other methods that improve signal quality, e.g., multi-echo fMRI⁵⁷. Approximately half of the scans
431 analysed herein utilised a multi-band acceleration protocol that may negatively affect signal-to-noise⁵⁸,
432 though these effects may be less pronounced for task-free imaging as performed here⁵⁹. We corrected for
433 estimated physiological noise using aCompCor but did not statistically model physiological effects such as
434 changes in respiration, heart rate, or vasoconstriction which are affected by psilocybin and may have
435 confounded our findings^{60,61}. Our statistical models assume a close temporal relation between brain entropy
436 and PsiFx (measured adjacent to scans), thus, if changes in brain entropy occur after PsiFx, they would not
437 be well captured.

438 Pre-processing

439 A prevailing challenge in fMRI research is how best to handle the enormous flexibility in data pre-
440 processing⁶². Here we explored this space by evaluating brain entropy metrics across a set of pre-processing
441 strategies. Most of our results were robust to using the original and common atlases, indicating robustness
442 to parcellation choice. We also considered six different denoising strategies. The associations with PsiFx
443 of some metrics (DCC distribution, Sample Entropy (scale 1), Meta-state complexity and Path-length
444 distribution) were robust to most pre-processing strategies, whereas some were sensitive to pre-processing
445 strategy, e.g., temporal BOLD complexity (LZct). For those metrics which remained significantly
446 associated with PsiFx across pipelines, the strength of some associations varied across pipelines. Notably,
447 the removing the low-pass filter and applying a relatively narrow bandpass filter both substantively affected
448 the statistical relations between PsiFx and brain entropy metrics. This is consistent with previous reports
449 that pre-processing decisions can influence observed effects on fMRI outcome measures⁶², which
450 underscores the need for future studies in large, normative datasets probing brain entropy metric
451 characteristics in the context of this pre-processing multiverse. This is all the more relevant to advance their
452 predictive or prognostic utility in clinical cohorts.

453
454 We provide a public MATLAB-toolbox, the Copenhagen Brain Entropy toolbox (CopBET
455 <https://github.com/anders-s-olsen/CopBET>), containing functions to evaluate each of the entropy metrics
456 evaluated here, allowing future studies to determine how these entropy metrics are affected by the multitude
457 of possible fMRI pre-processing pipelines. For the purposes of this manuscript, we show that our pre-
458 processing pipeline was very similar to all previously applied in this space (See Supplementary Table S7)
459 and thus believe that our results are directly comparable with previously reported findings. We have shown
460 that one of our findings was more strongly supported using a multi-band sequence (path-length distribution)
461 and another when not using multi-band (Long-scale Sample Entropy). Further work may therefore also
462 wish to apply CopBET to data collected using a range of scanning sequences to evaluate the effect of
463 scanning parameters such as multi-band acceleration or multi-echo recording. However, given the
464 enormous number of possible parameter choices and the unsupervised nature of the problem, interpretation
465 of results from such an analysis remains a challenge⁶².

466 Conclusion

467 In conclusion, we observed acute effects of psilocybin on 3 of 13 previously reported brain entropy metrics.
468 We report novel evidence for a strong association effect on DCC distribution entropy, implicating it as a
469 potential biomarker of acute psychedelic effects. We also present convergent evidence for weak
470 associations with increases in path-length distribution entropy. In addition, two Lempel Ziv complexity
471 measures showed marginal associations with psilocybin measures. We did not observe significant
472 associations for 8 of 13 metrics evaluated, suggesting nuanced support for the popular theory that
473 psychedelics acutely increase brain entropy. Our observations implicate potential brain biomarkers of acute
474 psychedelic effects and emphasise the need for both transparency in reporting brain entropy metrics and
475 corroborating previously reported findings in independent datasets.

476 Methods

477 Twenty-eight healthy volunteers participated in the study (10 female, mean age \pm SD : 33 ± 8) and were
478 recruited from a database of individuals interested in participating in a study involving psychedelics. A
479 detailed description of the study design can be found in the Supplementary Text and has been reported
480 previously⁶⁴. The study protocol was approved by the ethics committee of the capital region of Copenhagen
481 (H-16026898) and the Danish Medicines Agency (EudraCT no.: 2016-004000-61). The study was
482 registered at clinicaltrials.gov (NCT03289949). Data presented here were collected between 2018 and 2021.
483 A subset of the functional brain imaging data presented here has been included in different studies reported
484 previously^{64,65}. Details of recruitment, procedures during the psilocybin session, ethical approvals, MRI
485 acquisition and quality control, are described in the Supplementary Text. Analyses were pre-registered on
486 the 3rd of August 2022 (<https://aspredicted.org/bw8y7.pdf>). Some analyses that met our inclusion criteria
487 (i.e., fMRI studies investigating entropy changes pertaining to psychedelics) were identified after pre-
488 registration and were added. No statistical methods were used to pre-determine sample sizes but our sample
489 sizes are larger than all previous publications (see Figure 1).

490 Data Collection

491 After obtaining written informed consent and screening for neurological, somatic and psychiatric illness,
492 participants completed a single-blind, cross-over study design wherein participants received a single 0.2-
493 0.3 mg/kg dose of psilocybin (mean \pm SD dose: 19.7 ± 3.6 mg, administered in units of 3 mg capsules) or
494 20 mg of ketanserin. Data from ketanserin scans are outside the scope of the current evaluation and not
495 presented here. After drug administration, participants completed MRI scan sessions including resting-state
496 fMRI (see Supplementary Text for details) approximately 40, 80, 130, and 300 minutes after administration.
497 Following each scan, participants were asked, "On a scale from 0 to 10 how intense is your experience right
498 now" to measure SDI and a venous blood-draw used to quantify PPL (see Supplementary Text for details).
499 After each resting-state fMRI scan, participants were asked if they had fallen asleep (no participants
500 reported doing so). Occ_{2A} , i.e., occupancy of psilocybin at the 5-HT_{2A} receptor is closely related to PPL
501 and SDI². Here we applied the previously reported parameter estimates relating PPL to occupancy based
502 on the Hill-Langmuir equation: $Occ_{2A} = \frac{Occ_{max} \times C_p}{EC_{50} + C_p}$ where Occ_{max} refers to the maximum measurable
503 occupancy, C_p refers to the measured concentration of the ligand in plasma (i.e., PPL), and EC_{50} refers to
504 the concentration in plasma at which occupancy is equal to 50% of Occ_{max} (fixed parameters used to
505 compute Occ_{2A} : $EC_{50} = 1.95 \mu\text{g/L}$ and $Occ_{max} = 76.6\%$).

506 Pre-processing

507 Pre-processing and denoising was uniform across all entropy metrics despite differences in the pipelines of
508 the original publications. Our pipeline included slice-timing correction (where applicable), unwarping,
509 realignment, co-registration of structural scans to functional data, segmentation, normalisation, and
510 smoothing. Two MR-scanners were used to acquire the data, and some functional data were temporally
511 downsampled so that the sampling frequency was consistent across scan sessions. Denoising in CONN⁶⁶
512 included linear detrending, aCompCor⁶⁷, 12-motion (three translations, three rotations and their first
513 derivatives) and artefact-flagged volume regression ($z > 4$ SDs or motion > 2 mm using ART), band-pass

514 filtering (0.008-0.09 Hz) and parcellation. Cerebellar ROIs were removed from included atlases as they
515 were not consistently within the field of view. See Supplementary Text for more details.

516 Entropy of Static Connectivity

517 Four studies evaluated the entropy of static connectivity given by the matrix of Pearson correlation
518 coefficients, \mathbf{R} , computed from N -regional time-series data^{27,33-35}, N being the number of ROIs in the atlas
519 used by the study.

520 Out-network Connectivity Distribution

521 Following a graph-theory framework, ROIs from the 200-region Craddock-atlas⁶⁸ were partitioned into
522 “networks” using the Louvain modularity algorithm applied to the average connectivity matrix across scan
523 sessions⁶⁹. The “Out-network Connectivity”, referred to as “diversity coefficient” in the original publication
524 and “Brain Connectivity Toolbox”^{27,70}, of an ROI was calculated for each scan session as the Shannon
525 entropy of the distribution of connectivity estimates between a given ROI and the set of ROIs assigned to
526 a different network.

527 Degree Distribution

528 Degree refers to the number of non-zero elements in any given row of a thresholded matrix. ROI-specific
529 degrees are computed based on \mathbf{R} , the Pearson correlation matrix between ROIs, with $N=105$ using the
530 Harvard-Oxford-105 atlas⁷¹. Both this analysis and Path-length distribution use the absolute correlation
531 values. The thresholding for this analysis occurred in two steps. In the first step, any correlation for which
532 the corresponding p-value was above 0.05 was set to 0. In the second step the goal is to reach a pre-specified
533 mean degree across rows. In order to achieve this, a threshold below which all absolute values are set to 0
534 is gradually increased until the mean number of non-zero elements is at the desired level. Here we applied
535 a scan-specific threshold that produced a mean degree of 27 because this was the threshold that produced
536 the largest effect in the original publication³⁵. This means that each scan may have a different absolute
537 threshold value, but identical mean degree. The final entropy quantification is simply the Shannon entropy
538 of the distribution of degrees across ROIs. We also calculated entropy for mean degrees of 1 up to the point
539 at which for any given scan session an increase in absolute threshold did not produce an increase in mean
540 degree, i.e., 48. This also applies to the path-length entropy described below.

541 Path-length Distribution

542 Again using absolute correlation values, the matrix was thresholded using only the mean-degree criteria
543 and not the p-value threshold. The matrix was then binarised, setting all non-zero elements to 1. The
544 “shortest path length” was then computed as the fewest edges one must traverse to go from one node to
545 another. The Shannon entropy of the distribution of path lengths from each node to all other nodes was then
546 calculated³⁴. Path-length distribution was evaluated for correlation coefficient thresholds up to a mean
547 degree of 53.

548 Von Neumann Entropy

549 Entropy of the Pearson correlation matrix, \mathbf{R} , derived for the Harvard-Oxford-105 atlas, was calculated
550 through the von Neumann entropy: $S(\mathbf{p}) = -\sum_{i=1}^N \lambda_i \log \lambda_i$, where λ are the eigenvalues of the scaled
551 correlation matrix $\mathbf{p}=\mathbf{R}/N$. The von Neumann entropy may also be defined as $S(\mathbf{p}) = -\text{tr}(\mathbf{p}\log\mathbf{p})$, where \log
552 represents the matrix logarithm ³³.

553 Entropy of Dynamic Connectivity

554 Intra-network Synchrony Distribution

555 Nine brain networks were defined according to a previous study ⁷²: auditory, dorsal attention, default mode,
556 left and right frontoparietal, motor, salience, visual 1 and visual 2. For a given network, for a given time
557 point, the variance across voxels within the network was evaluated. The Shannon entropy was then
558 calculated on the histogram of the variance estimates over time ¹⁹.

559 Motif-connectivity Distribution

560 Dynamic functional brain connectivity was evaluated in four regions (10mm diameter spheres) located at
561 bilateral hippocampi, MNI coordinates: right: (26, -21, -16), left: (-34, -22, -16), and anterior cingulate
562 cortices, right: (4, 35, 18), left: (-2, 23, 28) using a non-overlapping sliding window approach with varying
563 window lengths (15-150s). In each window, the partial correlation coefficient and corresponding p-value
564 was calculated for every region pair, controlling for the remaining regions and the motion framewise
565 displacement time-series. These time-series were standardised before windowing. The 4 x 4 partial
566 correlation matrix was binarised for every window, according to a corrected significance threshold
567 $p=0.0083$ (i.e., $0.05/6$, where 6 is the number of region pairs). A probability distribution of the frequency
568 of each of the 64 possible graph structures was established and the Shannon entropy was calculated ²⁸.

569 LEiDA-state Markov-rate

570 Notably, this entropy metric was not applied to evaluate psychedelic effects in the original paper. Rather,
571 the authors provided a computational framework wherein parameters were learned by optimising this
572 entropy measure. For each scan session, Leading Eigenvector Dynamics Analysis (LEiDA) ⁷³ was applied
573 to the time-series of 90 AAL atlas regions ⁷⁴. The phase series was computed using the Hilbert transform
574 and, for each time point, a phase coherence matrix was estimated based on the cosine of the difference
575 between pairwise instantaneous phases. The phase coherence matrices were decomposed using the
576 eigenvalue decomposition and the first eigenvector was retained for every time point. The set of
577 eigenvectors was clustered using K -means with $K = 3$ states. Subsequently, the transition probability matrix
578 was computed for each scan session. The entropy rate of the transition matrix, $P(i, j)$, for each state, i , was
579 calculated as $S_i = -p(i) \sum_{j=1}^K P(i, j) \log P(i, j)$, where, p is the leading eigenvector of P . The final entropy
580 measure is given as $S = \sum_{i=1}^K S_i / \log_2(K)$ ²⁶.

581 Dynamic Conditional Correlation Distribution

582 Regional time-series were evaluated for each of the regions described in the Shen 268 region atlas ⁷⁵.
583 Windowless framewise correlation coefficients were calculated for all edges using the Dynamic
584 Conditional Correlation (DCC) toolbox ⁷⁶. Subsequently, the probability distribution over each ROI-to-ROI
585 DCC time-series was established, and the Shannon entropy was calculated. Each ROI was assigned to one
586 of eight networks: default mode, fronto-parietal, medial-frontal, motor, subcortical-cerebellar, visual
587 association, visual 1, and visual 2. Each ROI-to-ROI pair was assigned to its respective network-to-network
588 association (e.g., motor-to-motor, default mode-to-motor) and the mean entropy of each network-to-
589 network association was calculated. Although the original publication applies bin-width correction, they do
590 not report an effect of bin width and we report findings using MATLAB's *histcounts* function, which
591 automatically calculates bin-width ³⁶. Thus, we did not implement bin-width correction.

592 Meta-state Complexity

593 Regional time-series were evaluated for each of the regions described in the Lausanne 463 region atlas ⁷⁷.
594 BOLD time-series across all scan sessions were clustered using *K*-means into $K = 4$ states using the Pearson
595 correlation distance metric. The clustering procedure was repeated 200 times with random initialisations
596 and the best repeat in terms of *K*-means loss was extracted. The four states were grouped into two meta-
597 states because the clustering procedure typically produces sign-symmetric states. Each volume was
598 assigned to meta-state 0 or 1 and the Lempel-Ziv complexity (LZ76 exhaustive algorithm) of this binary
599 sequence was calculated ³¹.

600 Integration/Segregation-state Distribution

601 Regional time-series were evaluated for each region described in the Schaefer 200 region atlas ⁴⁴,
602 augmented with 32 subcortical regions from the Tian atlas ⁴³. A sliding-window correlation analysis was
603 performed using a window defined by convolving a rectangular window of size 44 seconds with a temporal
604 Gaussian kernel (FWHM = 3s). The correlation matrix was established for each window (stride of 1), and
605 the Louvain modularity algorithm ⁶⁹ was applied to estimate the module degree *z*-score and participation
606 coefficient for each region. The Louvain modularity algorithm was repeated 100 times to ensure an optimal
607 assignment. *K*-means clustering with $K = 2$ states was applied to a cartographic profile, i.e., a two-
608 dimensional unnormalised histogram of these measures, using the correlation distance and 500 replications.
609 The Shannon entropy was computed on the probability distribution of state occurrences ³⁰.

610 Entropy of Regional Dynamics

611 Multi-scale Sample Entropy

612 Networks were defined using the Yeo 17-network atlas ⁷⁸. Sample entropy is defined as the negative
613 logarithm of the conditional probability that if two vectors with length m (set to 2) are dissimilar below a
614 threshold distance r (set as 0.3), then vector pairs with length $m + 1$ will also have distance below the
615 threshold ²¹. Scales 1-5 were evaluated for each network, meaning that each time-series was split into non-
616 overlapping windows of length (scale) s volumes and the means of each window were concatenated to form
617 a condensed time-series upon which sample entropy was calculated ²⁹.

618 BOLD Complexity

619 Regional time-series were evaluated for each of the regions described in the Schaefer 1000 region atlas⁴⁴.
620 BOLD time-series for each ROI were first Hilbert-transformed. The amplitude of the Hilbert series was
621 then binarised around the mean amplitude for that region, i.e., assigned as “1” if greater than the mean and
622 “0” if less. These binarised time-series were combined into an $T \times N$ matrix, where $N = 1000$ is the
623 number of regions and T and is the number of time points. This matrix was collapsed into a single vector to
624 compute 1) the Lempel-Ziv complexity over time (LZct, LZ78 algorithm) wherein regional time-series
625 were concatenated or 2) Lempel-Ziv complexity over space (LZcs) wherein time-adjacent “region series”
626 were concatenated. LZct represents a calculation of the temporal entropy of each ROI, whereas LZcs
627 represents a calculation of the spatial entropy at each timepoint. The original publication³² reported only
628 LZcs, but LZct is also described in⁴⁷ whom Varley and colleagues reference as the source of their methods.

629 Statistical Model

630 Effects of psilocybin on brain entropy metrics were estimated using a linear mixed effects model with
631 relevant R packages, i.e., *predictmeans* (v1.0.6), *lme4* (v1.1.30), *nlme* (v3.1.157), *lmerTest* (v3.1.3) and
632 *LMMstar* (v0.7.6). We regressed each metric against each of the three measures (PPL, SDI, or Occ_{2A})
633 separately with a subject-specific random intercept and adjusting for motion, age, sex, and scanner. A test
634 statistic for the association between metric and measure was obtained using the Wald statistic. To ensure
635 adequate control of the family-wise error rate (FWER) across regions within each of the 13 metrics, (e.g.,
636 17 networks for one time scale of multi-scale sample entropy), we calculate p_{FWER} adjusted using the maxT
637 test method⁴² in a permutation framework similar to⁷⁹, employing 10000 permutations. As such, if
638 observed data superseded all permutations, the p-value is reported as $p < 0.0001$. “Motion” reflects the
639 framewise displacement computed using the Artifact Detection Toolbox (ART) (see Supplementary Text)
640 and “scanner” controls for MR scanner, of which there were two. We do not adjust p-values across metrics,
641 nor across SDI, PPL and Occ_{2A}; unadjusted p-values are reported for non-regional metrics as p_{perm} . We
642 defined findings as statistically significant if they were associated with all three psilocybin effects, SDI,
643 PPL and Occ_{2A} (collectively summarised “PsiFx”) at $p_{\text{perm}} < 0.05$ for non-regional metrics or $p_{\text{FWER}} < 0.05$
644 for regional metrics. Effect sizes are reported as Pearson’s correlation coefficient between the partial
645 residuals of the entropy metrics (adjusted for covariates using the mixed-model described above) and each
646 of PsiFx. The strength of Pearson’s correlation coefficients for significant associations are described as
647 “weak” (≤ 0.3), “moderate” (> 0.3 and ≤ 0.6), or “strong” (> 0.6) as previously defined⁸⁰.

648

649 Moderating Effect of Scanner

650 Our data were collected on one of two MRI scanners. In order to investigate whether scanner choice had an
651 impact on the estimated relation between PPL and entropy moderating effects of scanner were explored in
652 separate models that included the scanner-x-PPL interaction as an additional covariate.

653 Correlation Between Metrics

654 Simple Pearson correlation coefficients were calculated between each whole-brain entropy metric pair as
655 well as with motion. Of the two graph theory metrics requiring thresholding, the threshold producing a

656 mean degree of 27 was used. For the motif-connectivity distribution, 15 and 100 second windows were
657 selected to represent fast and slow dynamics, respectively. P-values were adjusted using Bonferroni
658 correction⁸¹. All scans remaining after pre-processing were used in these analyses.

659 Effect of Parcellation

660 To explore parcellation effects on outcomes, all entropy metrics were evaluated using the Schaefer 100
661 region atlas with 16 subcortical regions from the Tian atlas^{43,44}. For metrics using network definitions, the
662 Yeo 7-network atlas was applied as a common atlas.

663 Effect of Pre-processing Pipelines

664 To explore the effect of pre-processing decisions on the associations between PsiFx and brain entropy
665 metrics, analyses were repeated for six additional pre-processing pipelines. Each pre-processing pipeline
666 was run on the data parcellated as described in the section “Effect of parcellation” i.e., 116 ROIs assigned
667 to seven networks. Each pipeline changed one variable from the “reference” pipeline. These were as
668 follows: 1) adding global signal regression, 2) removing the low-pass 0.09 Hz filter (i.e., not removing
669 high-frequency signal), 3) expanding the 12-motion regressors to include squares of the derivatives (i.e.,
670 Volterra expansion), 4) not regressing out flagged volumes 5) regressing flagged volumes with a stricter
671 threshold ($z > 3$ or $\text{motion} > 0.5\text{mm}$), (6) applying a narrower bandpass filter (0.03-0.07 Hz).

672 Code and Data Availability

673 We shared relevant analysis scripts with original authors, hoping to ensure as much as possible that our
674 computations aligned with original reports; we are thankful for the feedback we received. All functions
675 used to derive entropy estimates from pre-processed data have been compiled into the "Copenhagen Brain
676 Entropy Toolbox" (CopBET), a Matlab-based toolbox that can be found here: <https://github.com/anders-s-olsen/CopBET>. The permutation testing code is also available here. Code for other statistical analyses and
677 figures can be made available upon request. The data that support the findings of this study are available
678 from the corresponding author upon request to the CIMBI database⁸².

680 Acknowledgements

681 A sincere thank you to Andrea Luppi, Enzo Tagliazucchi, Alexander Lebedev, Manoj Doss, Thomas
682 Varley, and Parker Singleton for their advice and feedback regarding their entropy metrics, including advice
683 from Drs Doss and Varley to not use their entropy metrics, as they no longer believed them to be valid,
684 which we appreciate, but disregarded.

685 Conflict Statement

686 DEWM salary is supported by an unrestricted grant from COMPASS Pathways who have no involvement
687 in the preparation or conception of this manuscript or related data collection. MKM has received an
688 honorarium as a speaker for H. Lundbeck. GMK has served as a consultant for Sanos, Gilgamesh, Onsero,

689 Pangea, Abbvie, PureHealthTech, and has received honoraria as speaker for H. Lundbeck and Sage
690 Therapeutics.

691 Author Contributions

692 DEWM conceptualised the manuscript idea, collected data, performed analyses, and wrote the manuscript.
693 ASO conceptualised the manuscript idea, performed analyses, prepared the CopBET, and wrote the
694 manuscript. BO supported statistical analyses and related software. DSS facilitated, supervised, and
695 performed data collection. SA performed data collection. MKM conceptualised the original study, and
696 facilitated and performed data collection. GMK obtained core study funding, conceptualised the original
697 study, and provided feedback on the project. PMF conceptualised the original study, facilitated data
698 collection, and supervised data analysis and manuscript writing. All co-authors reviewed the manuscript,
699 provided feedback, and approved the final version.

References

- 700
701
702 1. Becker, A. M. *et al.* Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a
703 Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. *Clin.*
704 *Pharmacol. Ther.* **111**, 886–895 (2022).
- 705 2. Madsen, M. K. *et al.* Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy
706 and plasma psilocin levels. *Neuropsychopharmacology* **44**, 1328–1334 (2019).
- 707 3. Nichols, D. E. Psychedelics. *Pharmacol. Rev.* (2016) doi:10.1124/pr.115.011478.
- 708 4. Wallach, J. *et al.* Identification of 5-HT_{2A} receptor signaling pathways associated with psychedelic
709 potential. *Nat. Commun.* **14**, 8221 (2023).
- 710 5. Anderson, B. T. *et al.* Psilocybin-assisted group therapy for demoralized older long-term AIDS
711 survivor men: An open-label safety and feasibility pilot study. *EClinicalMedicine* **27**, 100538 (2020).
- 712 6. Bogenschutz, M. P. *et al.* Percentage of Heavy Drinking Days Following Psilocybin-Assisted
713 Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder. *JAMA*
714 *Psychiatry* **79**, 953 (2022).
- 715 7. Carhart-Harris, R. *et al.* Trial of Psilocybin versus Escitalopram for Depression. *N. Engl. J. Med.* **384**,
716 1402–1411 (2021).
- 717 8. Carhart-Harris, R. L. *et al.* Psilocybin with psychological support for treatment-resistant depression:
718 six-month follow-up. *Psychopharmacology (Berl.)* **235**, 399–408 (2018).
- 719 9. Goodwin, G. M. *et al.* Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
720 *N. Engl. J. Med.* **387**, 1637–1648 (2022).
- 721 10. Griffiths, R. R. *et al.* Psilocybin produces substantial and sustained decreases in depression and anxiety
722 in patients with life-threatening cancer: A randomized double-blind trial. *J. Psychopharmacol. (Oxf.)*
723 **30**, 1181–1197 (2016).
- 724 11. Holze, F., Gasser, P., Müller, F., Dolder, P. C. & Liechti, M. E. Lysergic Acid Diethylamide–Assisted
725 Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized,

- 726 Double-Blind, Placebo-Controlled Phase II Study. *Biol. Psychiatry* (2022)
727 doi:10.1016/j.biopsych.2022.08.025.
- 728 12. Johnson, M. W., Garcia-Romeu, A. & Griffiths, R. R. Long-term follow-up of psilocybin-facilitated
729 smoking cessation. *Am. J. Drug Alcohol Abuse* **43**, 55–60 (2017).
- 730 13. Griffiths, R. R. *et al.* Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-
731 related effects. *Psychopharmacology (Berl.)* **218**, 649–665 (2011).
- 732 14. McCulloch, D. E.-W. *et al.* Psilocybin-Induced Mystical-Type Experiences are Related to Persisting
733 Positive Effects: A Quantitative and Qualitative Report. *Front. Pharmacol.* **13**, 1–17 (2022).
- 734 15. Schmid, Y. & Liechti, M. E. Long-lasting subjective effects of LSD in normal subjects.
735 *Psychopharmacology (Berl.)* **235**, 535–545 (2018).
- 736 16. McCulloch, D. E.-W. *et al.* Psychedelic resting-state neuroimaging: A review and perspective on
737 balancing replication and novel analyses. *Neurosci. Biobehav. Rev.* **138**, 104689 (2022).
- 738 17. Doss, M. K. *et al.* Models of psychedelic drug action: modulation of cortical-subcortical circuits. *Brain*
739 (2021) doi:10.1093/brain/awab406.
- 740 18. Carhart-Harris, R. L. The entropic brain - revisited. *Neuropharmacology* **142**, 167–178 (2018).
- 741 19. Carhart-Harris, R. L. *et al.* The entropic brain: A theory of conscious states informed by neuroimaging
742 research with psychedelic drugs. *Front. Hum. Neurosci.* **8**, 1–22 (2014).
- 743 20. Shannon, C. E. A mathematical theory of communication. *Bell Syst. Tech. J.* **27**, 379–423 (1948).
- 744 21. Delgado-Bonal, A. & Marshak, A. Approximate Entropy and Sample Entropy: A Comprehensive
745 Tutorial. *Entropy* **21**, 541 (2019).
- 746 22. Lempel, A. & Ziv, J. On the Complexity of Finite Sequences. *IEEE Trans. Inf. Theory* **22**, 75–81
747 (1976).
- 748 23. Richman, J. S. & Moorman, J. R. Physiological time-series analysis using approximate entropy and
749 sample entropy maturity in premature infants Physiological time-series analysis using approximate
750 entropy and sample entropy. *Am. J. Physiol. Heart Circ. Physiol.* **278**, H2039–H2049 (2000).

- 751 24. Ziv, J. & Lempel, A. Compression of individual sequences via variable-rate coding. *IEEE Trans. Inf.*
752 *Theory* **24**, 530–536 (1978).
- 753 25. Rubinov, M. & Sporns, O. Complex network measures of brain connectivity: Uses and interpretations.
754 *NeuroImage* **52**, 1059–1069 (2010).
- 755 26. Kringelbach, M. L. *et al.* Dynamic coupling of whole-brain neuronal and neurotransmitter systems.
756 *Proc. Natl. Acad. Sci.* **117**, 9566–9576 (2020).
- 757 27. Lebedev, A. V. *et al.* Finding the self by losing the self: Neural correlates of ego-dissolution under
758 psilocybin: Finding the Self by Losing the Self. *Hum. Brain Mapp.* **36**, 3137–3153 (2015).
- 759 28. Tagliazucchi, E., Carhart-Harris, R., Leech, R., Nutt, D. & Chialvo, D. R. Enhanced repertoire of brain
760 dynamical states during the psychedelic experience. *Hum. Brain Mapp.* **35**, 5442–5456 (2014).
- 761 29. Lebedev, A. V. *et al.* LSD-induced entropic brain activity predicts subsequent personality change:
762 LSD-Induced Entropic Brain Activity. *Hum. Brain Mapp.* **37**, 3203–3213 (2016).
- 763 30. Luppi, A. I. *et al.* LSD alters dynamic integration and segregation in the human brain. *NeuroImage*
764 **227**, 117653 (2021).
- 765 31. Singleton, S. P. *et al.* Receptor-informed network control theory links LSD and psilocybin to a
766 flattening of the brain’s control energy landscape. *Nat. Commun.* **13**, 5812 (2022).
- 767 32. Varley, T. F., Carhart-Harris, R., Roseman, L., Menon, D. K. & Stamatakis, E. A. Serotonergic
768 psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and
769 temporal domains. *NeuroImage* **220**, 117049 (2020).
- 770 33. Felipe, H. *et al.* The von Neumann entropy for the Pearson correlation matrix: A test of the entropic
771 brain hypothesis. in (2021).
- 772 34. Viol, A. *et al.* Characterizing Complex Networks Using Entropy-Degree Diagrams: Unveiling Changes
773 in Functional Brain Connectivity Induced by Ayahuasca. *Entropy 2019 Vol 21 Page 128* **21**, 128
774 (2019).


- 775 35. Viol, A., Palhano-Fontes, F., Onias, H., De Araujo, D. B. & Viswanathan, G. M. Shannon entropy of
776 brain functional complex networks under the influence of the psychedelic Ayahuasca. *Sci. Rep.* **7**, 1–
777 13 (2017).
- 778 36. Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J. & Griffiths, R. R. Emotions and brain function
779 are altered up to one month after a single high dose of psilocybin. *Sci. Rep.* **10**, 2214 (2020).
- 780 37. Kung, Y.-C. *et al.* Cross-Scale Dynamicity of Entropy and Connectivity in the Sleeping Brain. *Brain*
781 *Connect.* **12**, 835–845 (2022).
- 782 38. Maki-Marttunen, V., Diez, I., Cortes, J., Chialvo, D. & Villarreal, M. Disruption of transfer entropy
783 and inter-hemispheric brain functional connectivity in patients with disorder of consciousness. *Front.*
784 *Neuroinformatics* **7**, (2013).
- 785 39. Pappas, I., Adapa, R. M., Menon, D. K. & Stamatakis, E. A. Brain network disintegration during
786 sedation is mediated by the complexity of sparsely connected regions. *NeuroImage* **186**, 221–233
787 (2019).
- 788 40. Chang, D. *et al.* Caffeine Caused a Widespread Increase of Resting Brain Entropy. *Sci. Rep.* **8**, 2700
789 (2018).
- 790 41. Doss, M. K. *et al.* The Acute Effects of the Atypical Dissociative Hallucinogen Salvinorin A on
791 Functional Connectivity in the Human Brain. *Sci. Rep.* (2020) doi:10.1038/s41598-020-73216-8.
- 792 42. Westfall, P. H. & Troendle, J. F. Multiple Testing with Minimal Assumptions. *Biom. J. Biom. Z.* **50**,
793 745–755 (2008).
- 794 43. Tian, Y., Margulies, D. S., Breakspear, M. & Zalesky, A. Topographic organization of the human
795 subcortex unveiled with functional connectivity gradients. *Nat. Neurosci.* (2020) doi:10.1038/s41593-
796 020-00711-6.
- 797 44. Schaefer, A. *et al.* Local-Global Parcellation of the Human Cerebral Cortex from Intrinsic Functional
798 Connectivity MRI. *Cereb. Cortex* (2018) doi:10.1093/cercor/bhx179.
- 799 45. Yang, A. C. *et al.* Decreased resting-state brain activity complexity in schizophrenia characterized by
800 both increased regularity and randomness. *Hum. Brain Mapp.* **36**, 2174–2186 (2015).

- 801 46. Nichols, D. E. & Walter, H. The History of Psychedelics in Psychiatry. *Pharmacopsychiatry* **54**, 151–
802 166 (2021).
- 803 47. Schartner, M. M., Carhart-Harris, R. L., Barrett, A. B., Seth, A. K. & Muthukumaraswamy, S. D.
804 Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin.
805 *Sci. Rep.* **7**, 46421 (2017).
- 806 48. Timmermann, C. *et al.* Human brain effects of DMT assessed via EEG-fMRI. *Proc. Natl. Acad. Sci.*
807 **120**, e2218949120 (2023).
- 808 49. Timmermann, C. *et al.* Neural correlates of the DMT experience assessed with multivariate EEG. *Sci.*
809 *Rep.* **9**, 16324 (2019).
- 810 50. Pallavicini, C. *et al.* Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural
811 settings. *J. Psychopharmacol. (Oxf.)* **35**, 406–420 (2021).
- 812 51. Murray, C. H. *et al.* Neural complexity is increased after low doses of LSD, but not moderate to high
813 doses of oral THC or methamphetamine. *Neuropsychopharmacology* 1–9 (2024) doi:10.1038/s41386-
814 024-01809-2.
- 815 52. Singleton, S. P. *et al.* Time-resolved network control analysis links reduced control energy under DMT
816 with the serotonin 2a receptor, signal diversity, and subjective experience. *BioRxiv Prepr. Serv. Biol.*
817 2023.05.11.540409 (2023) doi:10.1101/2023.05.11.540409.
- 818 53. Toker, D. *et al.* Consciousness is supported by near-critical slow cortical electrodynamics. *Proc. Natl.*
819 *Acad. Sci.* **119**, e2024455119 (2022).
- 820 54. Eckernäs, E., Timmermann, C., Carhart-Harris, R., Röshammar, D. & Ashton, M. N,N-
821 dimethyltryptamine affects electroencephalography response in a concentration-dependent manner—
822 A pharmacokinetic/pharmacodynamic analysis. *CPT Pharmacomet. Syst. Pharmacol.* **12**, 474–486
823 (2023).
- 824 55. Noble, S., Scheinost, D. & Constable, R. T. A decade of test-retest reliability of functional connectivity:
825 A systematic review and meta-analysis. *NeuroImage* **203**, 116157 (2019).


- 826 56. Birn, R. M. *et al.* The effect of scan length on the reliability of resting-state fMRI connectivity
827 estimates. *NeuroImage* **83**, 550–558 (2013).
- 828 57. Kundu, P. *et al.* Multi-echo fMRI: A review of applications in fMRI denoising and analysis of BOLD
829 signals. *NeuroImage* **154**, 59–80 (2017).
- 830 58. Risk, B. B. *et al.* Which multiband factor should you choose for your resting-state fMRI study?
831 *NeuroImage* **234**, 117965 (2021).
- 832 59. Demetriou, L. *et al.* A comprehensive evaluation of increasing temporal resolution with multiband-
833 accelerated protocols and effects on statistical outcome measures in fMRI. *NeuroImage* **176**, 404–416
834 (2018).
- 835 60. Dyer, D. C. & Gant, D. W. Vasoconstriction Produced by Hallucinogens on Isolated Human and Sheep
836 Umbilical Vasculature. *J. Pharmacol. Exp. Ther.* **184**, 366–375 (1973).
- 837 61. Holze, F., Becker, A. M., Kolaczynska, K. E., Duthaler, U. & Liechti, M. E. Pharmacokinetics and
838 Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants. *Clin. Pharmacol. Ther.*
839 **113**, 822–831 (2023).
- 840 62. Carp, J. On the Plurality of (Methodological) Worlds: Estimating the Analytic Flexibility of fMRI
841 Experiments. *Front. Neurosci.* **6**, (2012).
- 842 63. Van Essen, D. C. *et al.* The WU-Minn Human Connectome Project: An overview. *NeuroImage* (2013)
843 doi:10.1016/j.neuroimage.2013.05.041.
- 844 64. Madsen, M. K. *et al.* Psilocybin-induced changes in brain network integrity and segregation correlate
845 with plasma psilocin level and psychedelic experience. *Eur. Neuropsychopharmacol.* **50**, 121–132
846 (2021).
- 847 65. Olsen, A. S. *et al.* Psilocybin modulation of time-varying functional connectivity is associated with
848 plasma psilocin and subjective effects. *NeuroImage* 119716 (2022)
849 doi:10.1016/J.NEUROIMAGE.2022.119716.
- 850 66. Whitfield-Gabrieli, S. & Nieto-Castanon, A. Conn: A Functional Connectivity Toolbox for Correlated
851 and Anticorrelated Brain Networks. *Brain Connect.* (2012) doi:10.1089/brain.2012.0073.

- 852 67. Behzadi, Y., Restom, K., Liau, J. & Liu, T. T. A component based noise correction method (CompCor)
853 for BOLD and perfusion based fMRI. *NeuroImage* (2007) doi:10.1016/j.neuroimage.2007.04.042.
- 854 68. Craddock, R. C., James, G. A., Holtzheimer, P. E., Hu, X. P. & Mayberg, H. S. A whole brain fMRI
855 atlas generated via spatially constrained spectral clustering. *Hum. Brain Mapp.* (2012)
856 doi:10.1002/hbm.21333.
- 857 69. Blondel, V. D., Guillaume, J.-L., Lambiotte, R. & Lefebvre, E. Fast unfolding of communities in large
858 networks. *J. Stat. Mech. Theory Exp.* **2008**, P10008 (2008).
- 859 70. Bullmore, E. & Sporns, O. Complex brain networks: graph theoretical analysis of structural and
860 functional systems. *Nat. Rev. Neurosci.* **10**, 186–198 (2009).
- 861 71. Desikan, R. S. *et al.* An automated labeling system for subdividing the human cerebral cortex on MRI
862 scans into gyral based regions of interest. *NeuroImage* (2006) doi:10.1016/j.neuroimage.2006.01.021.
- 863 72. Smith, S. M. *et al.* Correspondence of the brain's functional architecture during activation and rest.
864 *Proc. Natl. Acad. Sci. U. S. A.* (2009) doi:10.1073/pnas.0905267106.
- 865 73. Cabral, J. *et al.* Cognitive performance in healthy older adults relates to spontaneous switching between
866 states of functional connectivity during rest. *Sci. Rep.* **7**, 5135 (2017).
- 867 74. Tzourio-Mazoyer, N. *et al.* Automated anatomical labeling of activations in SPM using a macroscopic
868 anatomical parcellation of the MNI MRI single-subject brain. *NeuroImage* (2002)
869 doi:10.1006/nimg.2001.0978.
- 870 75. Shen, X., Tokoglu, F., Papademetris, X. & Constable, R. T. Groupwise whole-brain parcellation from
871 resting-state fMRI data for network node identification. *NeuroImage* (2013)
872 doi:10.1016/j.neuroimage.2013.05.081.
- 873 76. Lindquist, M. A., Xu, Y., Nebel, M. B. & Caffo, B. S. Evaluating Dynamic Bivariate Correlations in
874 Resting-state fMRI: A comparison study and a new approach. *NeuroImage* **101**, 531–546 (2014).
- 875 77. Daducci, A. *et al.* The Connectome Mapper: An Open-Source Processing Pipeline to Map
876 Connectomes with MRI. *PLOS ONE* **7**, e48121 (2012).


- 877 78. Yeo, B. T. *et al.* The organization of the human cerebral cortex estimated by intrinsic functional
878 connectivity. *J. Neurophysiol.* (2011) doi:10.1152/jn.00338.2011.
- 879 79. Lee, O. E. & Braun, T. M. Permutation tests for random effects in linear mixed models. *Biometrics* **68**,
880 486–493 (2012).
- 881 80. Akoglu, H. User’s guide to correlation coefficients. *Turk. J. Emerg. Med.* **18**, 91–93 (2018).
- 882 81. Haynes, W. Bonferroni Correction. in *Encyclopedia of Systems Biology* 154–154 (Springer New York,
883 New York, NY, 2013). doi:10.1007/978-1-4419-9863-7_1213.
- 884 82. Knudsen, G. M. *et al.* The Center for Integrated Molecular Brain Imaging (Cimbi) database.
885 *NeuroImage* **124**, 1213–1219 (2016).
- 886
- 887



888



889



890

Entropy	Original dataset	Original findings	Our findings (original atlases)	Our findings (common atlas)
Static Connectivity				
Out-network connectivity	IV Psi	Region-specific effects	Not associated with PsiFx	Not associated with PsiFx
Degree distribution	Oral Aya	Increased	Not associated with PsiFx	Not associated with PsiFx
Path-length distribution	Oral Aya	Increased	Weak-moderate association with PsiFx†	Weak-moderate association with PsiFx‡
Von Neumann Entropy	Oral Aya	Numerically increased	Not associated with PsiFx	Not associated with PsiFx
Dynamic Connectivity				
Intra-network synchrony	IV Psi	Increased (some networks)	Not associated with PsiFx	Not associated with PsiFx
Motif-connectivity distribution	IV Psi	Increased	Not associated with PsiFx	Not atlas dependent
Meta-state complexity	IV Psi & IV LSD	No change	Weak association with SDI and Occ but not PPL	Weak association with Occ but not SDI or PPL
I/S state distribution	IV LSD	No change	Not associated with PsiFx	Not associated with PsiFx
LEiDA state Markov Rate	IV LSD	Not reported	Not associated with PsiFx	Weak negative association with all PsiFx
Edge-wise DCC distribution	Oral Psi*	No persisting change	Moderate-strong association with all PsiFx all networks except within motor cortex	Weak-strong association with all PsiFx in most networks
Dynamic Activity				
Multi-scale sample entropy	IV LSD	Increased at scales 1 2 and 3. Decreased at scale 5	Weak-moderate association with all PsiFx in several networks. Positive at scale 1, negative at scale 5	Weak-moderate association with all PsiFx in several networks. Positive at scale 1
BOLD complexity (spatial)	IV Psi & IV LSD	Increased (LSD) No change (psilocybin)	Not associated with PsiFx	Not associated with PsiFx
BOLD complexity (temporal)	IV Psi & IV LSD	Not reported	Weak association with SDI and Occ but not PPL	Not associated with PsiFx

*Investigates persisting effects at 1 week and 1 month post-psilocybin administration

† at thresholds producing a mean degree of 22-38

‡ at thresholds producing a mean degree of 31-38